Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
Cancer cells develop resistance to tyrosine kinase inhibitors targeting EGFR. Here, the authors explore the mechanism of resistance to one such inhibitor - osimertinib - and find that resistance is caused by increased expression and activation of the IGF1 receptor and subsequent activation of the do...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/286176aadbbc411dbfd32550becc33c5 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:286176aadbbc411dbfd32550becc33c5 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:286176aadbbc411dbfd32550becc33c52021-12-02T18:34:02ZTransient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer10.1038/s41467-020-18442-42041-1723https://doaj.org/article/286176aadbbc411dbfd32550becc33c52020-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-18442-4https://doaj.org/toc/2041-1723Cancer cells develop resistance to tyrosine kinase inhibitors targeting EGFR. Here, the authors explore the mechanism of resistance to one such inhibitor - osimertinib - and find that resistance is caused by increased expression and activation of the IGF1 receptor and subsequent activation of the donwstream signalling pathway.Rong WangTadaaki YamadaKenji KitaHirokazu TaniguchiSachiko AraiKoji FukudaMinoru TerashimaAkihiko IshimuraAkihiro NishiyamaAzusa TanimotoShinji TakeuchiKoshiro OhtsuboKaname YamashitaTomoyoshi YamanoAkihiro YoshimuraKoichi TakayamaKyoichi KairaYoshihiko TaniguchiShinji AtagiHisanori UeharaRikinari HanayamaIsao MatsumotoXujun HanKunio MatsumotoWei WangTakeshi SuzukiSeiji YanoNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-14 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Rong Wang Tadaaki Yamada Kenji Kita Hirokazu Taniguchi Sachiko Arai Koji Fukuda Minoru Terashima Akihiko Ishimura Akihiro Nishiyama Azusa Tanimoto Shinji Takeuchi Koshiro Ohtsubo Kaname Yamashita Tomoyoshi Yamano Akihiro Yoshimura Koichi Takayama Kyoichi Kaira Yoshihiko Taniguchi Shinji Atagi Hisanori Uehara Rikinari Hanayama Isao Matsumoto Xujun Han Kunio Matsumoto Wei Wang Takeshi Suzuki Seiji Yano Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer |
| description |
Cancer cells develop resistance to tyrosine kinase inhibitors targeting EGFR. Here, the authors explore the mechanism of resistance to one such inhibitor - osimertinib - and find that resistance is caused by increased expression and activation of the IGF1 receptor and subsequent activation of the donwstream signalling pathway. |
| format |
article |
| author |
Rong Wang Tadaaki Yamada Kenji Kita Hirokazu Taniguchi Sachiko Arai Koji Fukuda Minoru Terashima Akihiko Ishimura Akihiro Nishiyama Azusa Tanimoto Shinji Takeuchi Koshiro Ohtsubo Kaname Yamashita Tomoyoshi Yamano Akihiro Yoshimura Koichi Takayama Kyoichi Kaira Yoshihiko Taniguchi Shinji Atagi Hisanori Uehara Rikinari Hanayama Isao Matsumoto Xujun Han Kunio Matsumoto Wei Wang Takeshi Suzuki Seiji Yano |
| author_facet |
Rong Wang Tadaaki Yamada Kenji Kita Hirokazu Taniguchi Sachiko Arai Koji Fukuda Minoru Terashima Akihiko Ishimura Akihiro Nishiyama Azusa Tanimoto Shinji Takeuchi Koshiro Ohtsubo Kaname Yamashita Tomoyoshi Yamano Akihiro Yoshimura Koichi Takayama Kyoichi Kaira Yoshihiko Taniguchi Shinji Atagi Hisanori Uehara Rikinari Hanayama Isao Matsumoto Xujun Han Kunio Matsumoto Wei Wang Takeshi Suzuki Seiji Yano |
| author_sort |
Rong Wang |
| title |
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer |
| title_short |
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer |
| title_full |
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer |
| title_fullStr |
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer |
| title_full_unstemmed |
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer |
| title_sort |
transient igf-1r inhibition combined with osimertinib eradicates axl-low expressing egfr mutated lung cancer |
| publisher |
Nature Portfolio |
| publishDate |
2020 |
| url |
https://doaj.org/article/286176aadbbc411dbfd32550becc33c5 |
| work_keys_str_mv |
AT rongwang transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT tadaakiyamada transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT kenjikita transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT hirokazutaniguchi transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT sachikoarai transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT kojifukuda transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT minoruterashima transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT akihikoishimura transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT akihironishiyama transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT azusatanimoto transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT shinjitakeuchi transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT koshiroohtsubo transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT kanameyamashita transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT tomoyoshiyamano transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT akihiroyoshimura transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT koichitakayama transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT kyoichikaira transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT yoshihikotaniguchi transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT shinjiatagi transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT hisanoriuehara transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT rikinarihanayama transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT isaomatsumoto transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT xujunhan transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT kuniomatsumoto transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT weiwang transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT takeshisuzuki transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer AT seijiyano transientigf1rinhibitioncombinedwithosimertiniberadicatesaxllowexpressingegfrmutatedlungcancer |
| _version_ |
1718377907748864000 |